A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)

NCT01566279 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: Everolimus

Sponsor

UMC Utrecht